ZA989997B - Compositions of lipid lowering agents. - Google Patents

Compositions of lipid lowering agents.

Info

Publication number
ZA989997B
ZA989997B ZA9809997A ZA989997A ZA989997B ZA 989997 B ZA989997 B ZA 989997B ZA 9809997 A ZA9809997 A ZA 9809997A ZA 989997 A ZA989997 A ZA 989997A ZA 989997 B ZA989997 B ZA 989997B
Authority
ZA
South Africa
Prior art keywords
compositions
lowering agents
lipid lowering
lipid
agents
Prior art date
Application number
ZA9809997A
Other languages
English (en)
Inventor
Lieven Baert
Geert Verreck
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA989997B publication Critical patent/ZA989997B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9809997A 1997-11-03 1998-11-02 Compositions of lipid lowering agents. ZA989997B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97203407 1997-11-03

Publications (1)

Publication Number Publication Date
ZA989997B true ZA989997B (en) 2000-05-02

Family

ID=8228898

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9809997A ZA989997B (en) 1997-11-03 1998-11-02 Compositions of lipid lowering agents.

Country Status (20)

Country Link
US (1) US6342245B1 (de)
EP (1) EP1028730B1 (de)
JP (1) JP2001521899A (de)
KR (2) KR20010023661A (de)
CN (1) CN1278175A (de)
AR (1) AR013739A1 (de)
AT (1) ATE216238T1 (de)
AU (1) AU746890B2 (de)
BG (1) BG104338A (de)
BR (1) BR9814109A (de)
CA (1) CA2307097A1 (de)
DE (1) DE69804994D1 (de)
EE (1) EE200000186A (de)
HU (1) HUP0004139A3 (de)
NO (1) NO20002279D0 (de)
NZ (1) NZ503413A (de)
PL (1) PL340305A1 (de)
SK (1) SK5972000A3 (de)
WO (1) WO1999022738A1 (de)
ZA (1) ZA989997B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
US20030059487A1 (en) * 2001-09-21 2003-03-27 Niazi Sarfaraz K. Composition and method for the treatment of hypercholesterolemia and hyperlipidemia in mammals
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
US6455557B1 (en) * 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
MXPA06003452A (es) * 2003-09-26 2006-08-31 Johnson & Johnson Formulaciones de liberacion controlada que exhiben una velocidad de liberacion ascendente.
DE602004032149D1 (de) * 2003-09-26 2011-05-19 Alza Corp Oros-push-stick für die kontrollierte abgabe von wirkstoffen
EP2184058B1 (de) 2003-09-26 2012-02-08 ALZA Corporation Arzneistoffcoating mit hohem Wirkstoffanteil sowie Methoden zu dessen Herstellung
NZ546182A (en) * 2003-09-26 2009-08-28 Alza Corp Controlled release formulations of opioid and nonopioid analgesics such as hydrocodone and acetaminophen
CN101664411A (zh) 2003-11-14 2010-03-10 味之素株式会社 苯丙氨酸衍生物的固体分散体或固体分散体医药制剂
JP2008504229A (ja) * 2004-04-09 2008-02-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 過剰体重および肥満症患者のための間欠的投薬レジメン
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
JP2008542255A (ja) * 2005-05-27 2008-11-27 ファイザー・プロダクツ・インク 肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
ES2576633T3 (es) * 2005-08-08 2016-07-08 Abbvie Deutschland Gmbh & Co Kg Formas de dosificación con una biodisponibilidad mejorada
EP1938804A1 (de) * 2006-12-22 2008-07-02 Novartis AG Pharmazeutische Zubereitung enthaltend Neurokinin Antagonist
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
WO2010143199A1 (en) 2009-06-11 2010-12-16 Suven Nishtaa Pharma Private Limited Solid lipid dispersion for aqueous solubility enhancement of poorly water soluble drugs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521186A (en) * 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors
RO118715B1 (ro) * 1994-10-27 2003-09-30 Janssen Pharmaceutica Nv Inhibitori ai sintezei apolipoproteinei-b

Also Published As

Publication number Publication date
CN1278175A (zh) 2000-12-27
BG104338A (en) 2000-12-29
AU1157699A (en) 1999-05-24
SK5972000A3 (en) 2000-12-11
AU746890B2 (en) 2002-05-02
NO20002279L (no) 2000-04-28
AR013739A1 (es) 2001-01-10
BR9814109A (pt) 2000-10-03
JP2001521899A (ja) 2001-11-13
ATE216238T1 (de) 2002-05-15
KR20010023661A (ko) 2001-03-26
HUP0004139A2 (hu) 2002-02-28
US6342245B1 (en) 2002-01-29
PL340305A1 (en) 2001-01-29
NZ503413A (en) 2001-06-29
EP1028730A1 (de) 2000-08-23
HUP0004139A3 (en) 2002-03-28
KR20010023729A (ko) 2001-03-26
CA2307097A1 (en) 1999-05-14
NO20002279D0 (no) 2000-04-28
WO1999022738A1 (en) 1999-05-14
DE69804994D1 (de) 2002-05-23
EE200000186A (et) 2001-04-16
EP1028730B1 (de) 2002-04-17

Similar Documents

Publication Publication Date Title
HUP9903759A3 (en) Abtimicrobial compositions
GB9827475D0 (en) Compositions
EP1020194A4 (de) Öl/wasser emulsion zusammenstellungen
ZA989997B (en) Compositions of lipid lowering agents.
GB9702238D0 (en) Compositions
GB9715759D0 (en) New emulsion formulations
GB9711786D0 (en) Surfactant compositions
IL130856A0 (en) Peroxetine compositions
GB9707367D0 (en) Improved oil compositions
PL339174A1 (en) Lubricating compositions
GB9726543D0 (en) Novel compositions
GB9722691D0 (en) Emulsion composition
GB9724838D0 (en) Compositions
GB9707366D0 (en) Improved oil compositions
GB9705340D0 (en) Compositions
GB9703109D0 (en) Compositions
GB9710933D0 (en) Microemulsion compositions
GB9709826D0 (en) Improved oil composition
GB9705813D0 (en) Novel compositions
GB9712981D0 (en) Compositions
GB2336368B (en) Compositions
GB9708467D0 (en) Compositions
GB9709128D0 (en) Compositions
GB9722734D0 (en) Compositions
GB9719640D0 (en) Compositions